Enlivex Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENLV.TA research report →
Price Chart
About the company
Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in immunotherapy through macrophage reprogramming. The company's primary therapeutic candidate, Allocetra, is a cell-based treatment currently in a Phase II clinical trial for organ dysfunction and failure linked to sepsis.
- CEO
- Oren Hershkovitz
- IPO
- 2019
- Employees
- 77
- HQ
- Ness Ziona, IL
Get TickerSpark's AI analysis on ENLV.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $65.55M
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -1.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 248.08%
- ROIC
- -0.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-331,999+0.0%
- Op Income
- $-14,999,999
- Net Income
- $1.24B+8329.2%
- EPS
- $27.04+3804.1%
- OCF Growth
- +19.9%
- FCF Growth
- +20.0%
- 52W High
- $682.90
- 52W Low
- $213.20
- 50D MA
- $314.28
- 200D MA
- $341.40
- Beta
- 1.68
- RSI (14)
- 44
- Avg Volume
- 102.51K
No earnings-call transcripts are available for ENLV.TA yet.
- Free Float
- 99.5%
- Shares Outstanding
- 24.30M
- Float Shares
- 24.18M
Our ENLV.TA coverage
Recent articles, reports, and earnings notes.
No research on ENLV.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENLV.TA report →